Gainers
Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks.
Baudax Bio, Inc. (NASDAQ: BXRX) gained 109% to $0.6287 after the company announced it was granted orphan drug designation by the FDA for TI-168 for the treatment of Hemophilia A with inhibitors.
Chico's FAS, Inc. (NYSE: CHS) shares climbed 61.7% to $7.45 following the announcement of its acquisition by Sycamore Partners for $1 billion.
Aditxt, Inc. (NASDAQ: ADTX) gained 57% to $20.47.
Axcella Health Inc. (NASDAQ: AXLA) rose 31.3% to $9.08.
Inpixon (NASDAQ: INPX) shares gained 23.6% to $0.1729 after gaining around 10% on Wednesday.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) jumped 22.2% to $25.25. Soleno Therapeutics reported pricing of approximately $120 million underwritten public offering of common stock and concurrent private placement of common stock and/or pre-funded warrants.
Aytu BioPharma, Inc. (NASDAQ: AYTU) gained 22% to $2.33 following fourth-quarter results.
Organogenesis Holdings Inc. (NASDAQ: ORGO) gained 20.4% to $3.19.
Sarcos Technology and Robotics Corporation (NASDAQ: STRC) gained 20% to $0.80 after the company announced it was awarded a $13.8 million USD contract by the U.S. Air Force for the advancement of its AI and machine learning software.
Adamas One Corp. (NASDAQ: JEWL) gained 18% to $0.9200.
USA Compression Partners, LP (NYSE: USAC) climbed 14.7% to $25.94.
Gritstone bio, Inc. (NASDAQ: GRTS) gained 14.2% to $1.36.
Connexa Sports Technologies Inc. (NASDAQ: CNXA) gained 13.7% to $4.08. Connexa Sports Technologies recently announced that it received a letter from the Nasdaq regarding the late filing of its quarterly report.
VinFast Auto Ltd. (NASDAQ: VFS) climbed 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India.
Gritstone bio, Inc. (NASDAQ: GRTS) shares rose 13.5% to $1.3550 after the company announced it was awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a next-generation vaccine candidate for COVID-19 valued at ...
Benzinga
